21st International Congress » Therapy in Movement Disorders

Date: Tuesday, June 6, 2017

Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Meeting: 21st International Congress

1:45pm-3:15pm: A model community neurofitness and wellness center for people with Parkinson disease. 1-year group pilot data

E. Borchers, B. Farley, D. Snider, T. McIsaac, J. Bazan-Wigle (Tucson, AZ, USA)

1:45pm-3:15pm: A novel cause for unpredictable response to levodopa

J. Staisch, G. Bakis, J. Nutt (Portland, OR, USA)

1:45pm-3:15pm: A qualitative study of the views and experience of people with Parkinson’s disease regarding their footwear

A. Ashburn, M. Donnovan-Hall, J. Robison, M. Cole, C. Bowen, M. Burnett, L. Mamode, R. Pickering, D. Bader, D. Kunkel (Southampton, United Kingdom)

1:45pm-3:15pm: AAV-mediated over-expression of VEGF-B in PINK1 gene knockout rats increases striatal dopamine content

T. Falk, M. Bartlett, D. Muller, B. Silashki, D. Farrell, K. Parent, M. Heien, S. Sherman (Tucson, AZ, USA)

1:45pm-3:15pm: Alternative Apomorphine Challenge Test

J.C. Martinez Castrillo, A. Alonso Canovas, C. Estevez Fraga, G. Sanchez Diez, I. Avilés Olmos, J. Lopez Sendon, P. Garcia Ruiz, L. Vela Desojo (Madrid, Spain)

1:45pm-3:15pm: Antibody-Induced Failure of Botulinum Toxin Therapy: Restart with Incobotulinumtoxina Offers a New Opportunity

D. Dressler, F. Adib Saberi (Hamburg, Germany)

1:45pm-3:15pm: Antisense oligonucleotides containing amido-bridged nucleic acid downregulate SNCA expression and improve motor function in Parkinson’s disease mouse models.

T. Uehara, C.-J. Choong, H. Hayakawa, Y. Kasahara, T. Nagata, T. Yokota, K. Baba, M. Nakamori, S. Obika, H. Mochizuki (Suita-Shi, Osaka, Japan)

1:45pm-3:15pm: Barriers to exercise in newly diagnosed Parkinson’s disease

I. Argyropoulos, E. Pearson, F. Murphy, V. Queen, J. Rideout, C. Carrollq (Plymouth, United Kingdom)

1:45pm-3:15pm: Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial

Y. Dreissen, J. Dijk, J. Gelauff, E. Zoons, M. Contarino, R. Zutt, B. Post, D. van Poppelen, A. Munts, J. Speelman, R. de Haan, J. Koelman, M. Tijssen (Amsterdam, Netherlands)

1:45pm-3:15pm: CB2R agonist AM1241 reverses the development of MPTP-induced PD and activates the regeneration of DA neurons

R. Zhu (Shanghai, China)

1:45pm-3:15pm: Clinical Experience with Initiation of Carbidopa/Levodopa Enteral Suspension in Parkinson’s Disease Patients with Cognitive Impairment

P. Dowell, K. Lyons, R. Pahwa (Kansas City, KS, USA)

1:45pm-3:15pm: Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm

S. Pandey, S. Jain (New Delhi, India)

1:45pm-3:15pm: Closed Loop STN DBS for Tremor in Parkinson’s disease using a Neural or Kinematic Signal

A. Velisar, J. Herron, J. SYRKIN-NIKOLAU, Z. Blumenfeld, M. TRAGER, T. MARTIN, H. CHIZECK, H. Bronte-Stewart (Palo Alto, CA, USA)

1:45pm-3:15pm: Co-speech gestures in Parkinson’s disease (PD)

M. Bacigalupe (La Plata, Argentina)

1:45pm-3:15pm: Combined Motor and Cognitive Training Improves Motor and Cognitive Function in People with Parkinson’s Disease and Freezing of Gait

C. Fearon, I. Killane, L. Newman, R. Beck, T. Munteanu, D. Birsanu, J. Butler, B. Magennis, R. Reilly, T. Lynch (Dublin 7, Ireland)

1:45pm-3:15pm: Communication Calendar for Interdisciplinary Therapy of Parkinson’s Disease

F. Adib Saberi, D. Dressler (Hamburg, Germany)

1:45pm-3:15pm: Comparison of neurotoxic potency of a newly produced Botulinum Neurotoxin Type A with onabotulinumtoxinA, incobotulinumtoxinA and BotulinumtoxinA

Y. Feng, W. Liu, L. Pan, Z. Nie (Shanghai, China)

1:45pm-3:15pm: Design and discovery of 1,2,4 triazole derivatives as adenosine A2A receptor antagonist against parkinson’s disease

A. Verma, V. Kumar, U. Singh (Allahabad, India)

1:45pm-3:15pm: Design of a randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxin treatment for cervical dystonia (StimTox-CD)

H. Drechsel, U. Malzahn, C. Roeser, P. Heuschmann, J. Volkmann (Würzburg, Germany)

1:45pm-3:15pm: Determinant factors of treatment adherence in Parkinson’s disease

I. Estrada-Bellmann, C. Cerda-Contreras, J. Peña-Avendaño, D. Ortiz-Zacarías, P. Cortés-Estrada (Monterrey, Mexico)

1:45pm-3:15pm: Diphasic Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: diagnosis and management in clinical practice.

M. Marano, M. Marano, L. di Biase, R. Arca, G. Cossu, E. Coletta, V. Di Lazzaro, A. Fasano, P. Marano (Rome, Italy)

1:45pm-3:15pm: Direct dopaminergic responsiveness of activity performance

P. Hagell, G.-M. Hariz, B. Sandlund (Kristianstad, Sweden)

1:45pm-3:15pm: Dopamine replacement medication improves acquisition, retention, and transfer of skilled upper extremity movement in people with Parkinson Disease.

S. Paul, C. Walter, G. Olivier, L. Dibble, S. Schaefer (Salt Lake City, UT, USA)

1:45pm-3:15pm: Effects of non-invasive electrical and magnetic stimulation to improve motor and cognitive function in Parkinson’s disease: a meta-analytical review

A. Goodwill, J. Lum, A. Hendy, M. Muthalib, L. Johnson, N. Albein-Urios, W.-P. Teo (Burwood, Australia)

1:45pm-3:15pm: Evaluation of the short-term and long-term effects of an intensive multidisciplinary collective rehabilitation program over 5 weeks in Parkinson’s patients followed in Lyon

T. DANAILA, C. LAURENCIN, P. ROCHE, S. THOBOIS, M. CHEMINON, J. LUAUTE (BRON, France)

1:45pm-3:15pm: Exercise preferences of people with Parkinson’s disease: preliminary findings of a discrete choice experiment

C. Canning, C. Canning, S. Paul, J. Bampton, C. Sherrington, K. Howard (Lidcombe, Sydney, Australia)

1:45pm-3:15pm: Exercise Trends Reported in Parkinson’s Patients

P. Raje, C. Branson, M.P. de Leon, M. Saint-Hilaire, A. Hohler, S. Ning (Boston, MA, USA)

1:45pm-3:15pm: Fibroblasts Implanted in Internal Pallidum of Parkinsonian Macaques Exert L-Dopa-Sparing Activity

E. Bezard, J. Finberg, W.K. Ko, Q. Li, B. Dehay, E. Pioli, Y. Yair (Bordeaux, France)

1:45pm-3:15pm: Focused ultrasound subthalatomy restores intracortical inhibition in PD

M. Dileone, R. Martinez-Fernandez, M. Del Alamo, R. Rodriguez, J. Pineda-Pardo, F. Hernandez-Fernandez, J. Obeso, G. Foffani (Mostoles, Spain)

1:45pm-3:15pm: How Usual Is Skin Rashes During Treatment With Levodopa / Benserazide Hydrochloride?

E. Okuyucu, M. Uzel, S. Colakoglu Yesıldag, M. Guntel (Hatay, Turkey)

1:45pm-3:15pm: Impact of weekly dance classes on quality of life of individuals with Parkinson’s Disease.

L. Krejcova, J. Brito, W. Cohen, C. Bahia (Belem, Brazil)

1:45pm-3:15pm: Infusion Rate Dependent Acute Neuropathic Pain with Duopa™ in a Patient with Parkinson’s disease and Pre-Existing Neuropathy

A. Shukla, R. Govindarajan, I. Asher (Columbia, MO, USA)

1:45pm-3:15pm: Inhaling xenon ameliorates L-DOPA-induced dyskinesia in Parkinson disease through normalizing maladaptive corticostriatal plasticity

E. Bezard, J. Bauffreton, Q. Li, G. Porras, W.K. Ko, E. Pioli, M. Cazalon, S. Morin, G. Farjot, J. Pype, B. Bessiere (Bordeaux, France)

1:45pm-3:15pm: Interaction of dietary protein with levodopa in Parkinson disease.

B. Sharma, A. Rassmann, T. Virmani (Little Rock, AR, USA)

1:45pm-3:15pm: Intracerebroventricular administration of dopamine: A new therapeutic concept for Parkinson’s disease?

C. LALOUX, F. GOUEL, C. LACHAUD, K. Timmerman, A. Jonneaux, C. Moreau, R. BORDET, J.-c. DEVEDJIAN, D. DEVOS (LILLE, France)

1:45pm-3:15pm: Intrajejunal levodopa infusion (ILI) for Parkinson’s Disease (PD): A Canadian Experience

P. Podgorny, P. McCann, K. Toore, G. Tremain, A. Lazarescu, O. Suchowersky (Edmonton, AB, Canada)

1:45pm-3:15pm: Intranasal delivery of insulin for the restoration of memory signaling in Alzheimer disease

M. Bhargava, S. Bhargava, V. Bhargava (Kanpur, India)

1:45pm-3:15pm: Istradefylline improves motor symptoms in Parkinson’s disease: A meta-analysis

W. Sako, N. Murakami, K. Motohama, Y. Izumi, R. Kaji (Tokushima, Japan)

1:45pm-3:15pm: Low frequency Deep Brain stimulation for Parkinson’s disease – Effect on freezing of gait.

R. Gopalakrishnan, G. Hosurkar (Bangalore, India)

1:45pm-3:15pm: Managing severe dyskinesia in Parkinson’s Disease using 24-hour Levodopa/Carbidopa Intestinal Gel Infusion

B. Cruse, D. Tsui, J. Griffith, H. Morales-Briceno, F. Chang, A. Ha, S. Kim, N. Wolfe, V. Kwan, N. Mahant, V. Fung (Westmead, Australia)

1:45pm-3:15pm: More effective rTMS site for the freezing of gait in Parkinson’s disease

S.Y. Kang, S.J. Kim (Hwaseong, Republic of Korea)

1:45pm-3:15pm: Multidisciplinary Parkinson rehabilitation delays nursing home admission and is cost-effective.

E. Steendam-Oldekamp, W. Rutgers, T. van Laar (Groningen, Netherlands)

1:45pm-3:15pm: Neuroprotection and Alleviation of Parkinsonian Phenotypes by Ayurvedic Herbs

S. Singh, J. Prakash, S. Yadav (Varanasi, India)

1:45pm-3:15pm: Pairing TMS and physical therapy for treatment of gait and balance disorders in Parkinson’s Disease: a randomized pilot trial

A. Cucca, H. Migdadi, T. Biller, S. Agarwal, P. Kumar, A. Son, M. Ko, E. Gallo, S. Fisher, A. Di Rocco, M. Biagioni (New York, NY, USA)

1:45pm-3:15pm: Parkinson Syndrome associated with inositol-1,4,5-triphosphate receptor antigen type 1 (ITPR1) antibodies

B. Wimmer, K. Fuchs, U. Bogdahn, A. Heimeroth (Regensburg, Germany)

1:45pm-3:15pm: Parkinson’s Disease Medications Availability in Each Philippine Region

S. Villaraza, C. Go (Manila, Philippines)

1:45pm-3:15pm: Patients’ Perspective of Physicians’ Counseling on Exercise in Parkinson’s Disease (PD)

J.Y. Park, V. Shanker (New York, NY, USA)

1:45pm-3:15pm: Protocol for upper-limb kinematic analysis in paediatric movement disorders and relative normality data

L. Garavaglia, E. Pagliano, A. Lo Mauro, G. Baranello, A. Aliverti, S. Pittaccio (Lecco, Italy)

1:45pm-3:15pm: Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease

E. Tsika, E. Gabellieri, A. Davranche, C. Boudou, M. Ravache, L. Grasso, S. Nampally, H. Haddouk, J. Wettstein, A. Pfeifer, A. Muhs (Lausanne, Switzerland)

1:45pm-3:15pm: The influence of neurorehabilitation on Parkinson medication

V. Tomantschger, A. Tautscher-Basnett, M. Freimueller (Hermagor, Austria)

1:45pm-3:15pm: The therapeutic effects of cortical electrical stimulation in an animal model of Parkinson’s disease

T.-H. Hsieh, W.-S. Chang Chien, C.-W. Peng, Y.-Z. Hunag, J.-J. Chen (Taoyuan, Taiwan)

1:45pm-3:15pm: Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations

J. Mitsui, K. Koguchi, T. Momose, M. Takahashi, T. Matsukawa, T. Yasuda, S.-i. Tokushige, H. Ishiura, J. Goto, S. Nakazaki, T. Kondo, H. Ito, Y. Yamamoto, S. Tsuji (Tokyo, Japan)

1:45pm-3:15pm: Treadmill training, Tai Chi, dance and more: a meta-analysis on the effectiveness of different physiotherapy modalities in Parkinson’s disease

D. Radder, N. de Vries, M. Faber, M. van Nimwegen, S. Keus, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: Treatment of secondary movement disorders related to midbrain cavernomas

K. Karpinska, A. Smolanka (Uzhgorod, Ukraine)

1:45pm-3:15pm: Unusual facial synkinesia after Bell’s palsy: interactive Marin-Amat syndrome proven by surface electromyogram, successfully treated with low dose botulinum toxin A.

H. Mori (Kurashiki, Japan)

« View all sessions from the 21st International Congress.